Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Zironi

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
The International Journal of Biological Markers|October 1, 1991
Urinary neopterin in malignant lymphomaL Piccinini, S Zironi, M Federico, et al.
Tumori|June 30, 1990
Prevention of cisplatin-induced vomiting in patients with cancer. A pilot study with a multiagent protocolM Federico, R Sabbatini, P Piccinini, et al.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|September 1, 1993
Soluble interleukin-2 receptor and urinary neopterin concentrations in malignant lymphomaL Piccinini, S Zironi, A M Cenci, et al.
Breast Cancer Research and Treatment|August 6, 2002
Weight gain in women with breast cancer treated with adjuvant cyclophosphomide, methotrexate and 5-fluorouracil. Analysis of resting energy expenditure and body compositionG Del Rio, S Zironi, L Valeriani, et al.
American Journal of Clinical Oncology|June 1, 1996
High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)F Di Costanzo, M Tagliaventi, P Carlini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical ResearchG Cocconi, M Bella, S Zironi, et al.
British Journal of Cancer|September 16, 2010
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapyC Bengala, S Bettelli, F Bertolini, et al.
American Journal of Clinical Oncology|June 17, 2000
Modulation of fluorouracil by methotrexate, leucovorin, and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC)F Di Costanzo, R Canaletti, A Sdrobolini, et al.
British Journal of Cancer|November 26, 2009
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trialC Bengala, F Bertolini, N Malavasi, et al.
American Journal of Clinical Oncology|August 26, 1998
High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical ResearchF Di Costanzo, S Gasperoni, P Malacarne, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The International Journal of Biological Markers|October 1, 1991
Urinary neopterin in malignant lymphomaL Piccinini, S Zironi, M Federico, et al.
Tumori|June 30, 1990
Prevention of cisplatin-induced vomiting in patients with cancer. A pilot study with a multiagent protocolM Federico, R Sabbatini, P Piccinini, et al.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|September 1, 1993
Soluble interleukin-2 receptor and urinary neopterin concentrations in malignant lymphomaL Piccinini, S Zironi, A M Cenci, et al.
Breast Cancer Research and Treatment|August 6, 2002
Weight gain in women with breast cancer treated with adjuvant cyclophosphomide, methotrexate and 5-fluorouracil. Analysis of resting energy expenditure and body compositionG Del Rio, S Zironi, L Valeriani, et al.
American Journal of Clinical Oncology|June 1, 1996
High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)F Di Costanzo, M Tagliaventi, P Carlini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical ResearchG Cocconi, M Bella, S Zironi, et al.
British Journal of Cancer|September 16, 2010
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapyC Bengala, S Bettelli, F Bertolini, et al.
American Journal of Clinical Oncology|June 17, 2000
Modulation of fluorouracil by methotrexate, leucovorin, and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC)F Di Costanzo, R Canaletti, A Sdrobolini, et al.
British Journal of Cancer|November 26, 2009
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trialC Bengala, F Bertolini, N Malavasi, et al.
American Journal of Clinical Oncology|August 26, 1998
High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical ResearchF Di Costanzo, S Gasperoni, P Malacarne, et al.
Pageof 2